NCT06852807 18F-mFBG PET Imaging in the Evaluation of Neuroblastoma
| NCT ID | NCT06852807 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Neuroblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-02-04 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-02-04 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroblastoma.
Eligibility Criteria
Inclusion Criteria: 1. Age 0-18 years old, with legal guardian; 2. Clinically suspected or confirmed patients with neuroblastoma; 3. If the patient is under 8 years old or unable to write, his/her guardian should understand and comply with the requirements of the study. If the patient is 8 years old or older and has written ability, both the patient and his/her guardian must sign the informed consent. Exclusion Criteria: 1. Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system diseases; 2. Patients who have received ionizing radiation outside the scope of this experiment for other clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv. 3. Patients who have received experimental drugs or devices (with uncertain efficacy or safety) within one month; 4. Patients with any condition that the principal investigator of this study deems may cause harm or potential harm in any aspect related to this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06852807 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Neuroblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06852807 currently recruiting?
Yes, NCT06852807 is actively recruiting participants. Contact the research team at wpp199411@163.com for enrollment information.
Where is the NCT06852807 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06852807 clinical trial?
NCT06852807 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 200 participants.